Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-B7-H6/anti-CD3 bispecific antibody TGI-6

A bispecific antibody directed against both natural cytotoxicity triggering receptor 3 ligand 1 (NCR3LG1; B7-H6) and T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, anti-B7-H6/anti-CD3 bispecific antibody TGI-6 targets and binds to both B7-H6 on tumor cells and CD3 on T cells. This results in the cross-linking of B7-H6-expressing tumor cells and T cells, redirects cytotoxic T lymphocytes (CTLs) to B7-H6-expressing tumor cells, which leads to the CTL-mediated cell death of B7-H6-expressing tumor cells. B7-H6, a member of the B7 family of immune modulators, is expressed in a variety of tumor cell types while minimally or not expressed in normal tissues. It is a specific ligand for the natural killer (NK) cell activating receptor NKp30, and may modulate NK cell function in certain cancers.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-B7-H6/CD3 bispecific antibody TGI-6
B7-H6 x CD3 bispecific antibody TGI-6
Code name:TGI 6
TGI-6
TGI6
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search